Gouty Arthritis Clinical Trial
Official title:
Oral Huzhang Granules for Acute Gouty Arthritis: Protocol for a Randomized, Double-blind, Multicenter Clinical Trial
We designed this study as a double-blind, randomized, controlled clinical trial. The aim of the study is to evaluate the clinical efficacy, safety and control of recurrence rate of acute gouty arthritis
Status | Not yet recruiting |
Enrollment | 267 |
Est. completion date | August 31, 2023 |
Est. primary completion date | July 31, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility |
Inclusion Criteria: - Diagnosis of acute gout arthritis as defined by the American College of Rheumatology 1977 preliminary criteria; - Male or non-pregnant, non-nursing female; - 18-70 years of age; - Gout attack less =48 hours; - In the week before this observation, non-steroidal anti-inflammatory drugs and analgesic drugs and drugs affecting uric acid metabolism were not taken; - Subjects capable of giving informed consent; Exclusion Criteria: - failing to meet the diagnostic criteria; - Evidence of uncontrolled concomitant cardiovascular, nervous system,hepatic or gastrointestinal disease. Potential participants who have active concomitant disease can only be eligible after discussion and agreement with the treating medical team; - the patient is in critical condition and it is difficult to evaluate the effectiveness and safety of the clinical observation; - severe deformity, stiffness and labor loss of patients with advanced arthritis; - known allergic to the drug used in this study. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Shanghai Yueyang Integrated Medicine Hospital |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Visual Analogue Score (VAS) | Visual Analogue Score is an often-used tool to measure subjective phenomena, which has shown good reliability and validity in terms of assessment of pain. In the clinical study of acute gout attack,it can be used as a tool to measure the degree of pain from 0 to 100 mm (with 0 being no pain and 100 being maximum pain) | Up to 5 days after treatment | |
Secondary | Likert scales for the assessment of joint tenderness and swelling | Likert scales for the assessment of joint tenderness and swelling is evaluate the inflammatory response and the degree of injury of the joint.Scores range from 1-5, a higher score indicating a severe symptoms on a participant's joint | Up to 5 days after treatment | |
Secondary | symptom relief time | Symptom relief time is the time when joint pain feels relieved | Up to 5 days after treatment | |
Secondary | 36-Item Short Form Survey | 36-Item Short Form Survey is a health status profile originally designed to measure eight health concepts: physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perceptions. Scoring the 36-Item Health Survey is a two-step process. First, precoded numeric values are recoded per the scoring key in a given table. Note that all items are scored so that a high score defines a more favorable health state. In addition, each item is scored on a 0 to 100 range so that the lowest and highest possible scores are 0 and 100, respectively. Scores represent the percentage of total possible score achieved. In step 2, items in the same scale are averaged together to create the 8 scale scores. another lists the items averaged together to create each scale. Items that are left blank (missing data) are not taken into account when calculating |
Up to 5 days after treatment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT06068478 -
A Study to Evaluate Efficacy and Safety of Qingzhu Granules in the Treatment of Acute Gouty Arthritis
|
Phase 3 | |
Recruiting |
NCT01867840 -
Role of ASICs in Human Inflammatory Pain
|
N/A | |
Completed |
NCT00927810 -
Long Term Study of Canakinumab (ACZ885) in Patients With Gout
|
Phase 2 | |
Completed |
NCT05332795 -
The Impact of Metformin on the Outcome of Gouty Arthritis in a Cohort of Egyptian Gouty Patients.
|
N/A | |
Completed |
NCT05964946 -
Real-life Study of the Characteristics of Patients Treated With Ilaris® (Canakinumab) for Gouty Arthritis in France
|
||
Terminated |
NCT01362608 -
Safety & Efficacy of Canakinumab (ACZ885) in Patients With Frequent Flares for Whom Nonsterodial Anti-Inflammatory Drug (NSAIDs) and/ or Colchicine Are Contraindicated, Not Tolerated or Ineffective
|
Phase 3 | |
Completed |
NCT01626235 -
AMPED Outcomes Registry of Post-ED Pain Management
|
N/A | |
Recruiting |
NCT05658575 -
Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare
|
Phase 2/Phase 3 |